Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-060
Official listed status: posted
Closing information: 2027-10-20 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 750,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: County governments; City or township governments; Special district governments; Small businesses; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts
Federal synopsis
This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.